OpenCRISPR-1

A dated reading of what is claimed, reported, and independently verified in the current evidence.

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Watch

Primary summary from verified readiness

Evidence strength Strong

Decision

Agent-assisted assessment · independently reviewed · 2026-10-01

Consider adoption for controlled research after application-specific benchmarking.

Why: Independent experiments demonstrate useful editing in human cells and regenerated rice plants, but specificity advantages conflict across studies and depend on experimental context.
Next: Compare against established editors at your intended targets and delivery conditions, measure off-target effects, and confirm licensing terms. Therapeutic development requires additional safety and efficacy validation.

Constraints

Conflicting independent specificity results require application-specific testing.
Editing efficiency varies with cellular context and experimental configuration.
Plant off-target activity remains untested in the retained rice study.
Laboratory demonstrations do not establish therapeutic safety or efficacy.
Commercial therapeutic use requires a Profluent license agreement.

Evidence summary

AI-assisted assembly

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revision 4